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Abstract
Background: CD8+ regulatory T cells (Treg) have been considered to be involved in a model of
ocular-induced tolerance, known as anterior chamber-associated immune deviation (ACAID). The
phenotype and characteristics of CD8+Treg in ACAID remain only poorly understood. Recent
studies have reported that the CD94-Qa-1 system is implicated in the induction of ACAID
CD8+Treg, but the functions and characteristics of CD8+CD94+T cells remain unclear.
Results: Both mRNA and protein of CD94 and NKG2A were markedly up-regulated on splenic
CD8+T cells of ACAID mice compared with controls. Flow cytometric analysis showed that very
few CD8+CD94+T cells express granzyme B, perforin and Foxp3. CD8+CD94+T cells, but not
CD8+CD94-T cells, magnetically isolated from the spleens of ACAID mice, produced large
amounts of TGF-beta1 and exhibited suppressive activity in vitro. Neutralization of TGF-beta1
caused reversal of suppression mediated by CD8+CD94+T cells.
Conclusion: CD8+CD94+T cells from ACAID mice exhibited suppressive activity in association
with enhanced expression of TGF-beta1, suggesting that CD8+Treg are mainly distributed in
CD94+T cell subpopulations.
Background
Injection of soluble antigens (Ag) into the anterior cham-
ber (AC) of the eye induces systemic tolerance known as
anterior chamber-associated immune deviation (ACAID).
It is characterized by an antigen-specific suppression of
the delayed-type hypersensitivity (DTH) response and a
shift in antibody production away from complement-fix-
ing isotypes[1,2]. At least four organs or tissues including
an intact eye, spleen, thymus and sympathetic nervous
system are involved in the induction of ACAID, which
eventually generates two distinct regulatory T(Tregs) cell
populations in the spleen[3]. One population of Tregs
comprises CD4+T cells which function as afferent suppres-
sor cells and suppress the induction of a DTH response.
The other Treg cell population consists of CD8+T cells
which mediate an efferent suppression and inhibit the
expression of a DTH response. However, little is known
about the phenotype of CD8+Tregs in ACAID.
Published: 25 September 2008
BMC Immunology 2008, 9:53 doi:10.1186/1471-2172-9-53
Received: 29 April 2008
Accepted: 25 September 2008
This article is available from: http://www.biomedcentral.com/1471-2172/9/53
© 2008 He et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Immunology 2008, 9:53 http://www.biomedcentral.com/1471-2172/9/53
Page 2 of 11
(page number not for citation purposes)
The CD94 molecule belongs to the C-type lectin super-
family and forms a functional heterodimer with different
subtypes of NKG2 [4-6]. The CD94-NKG2 receptor was
originally discovered in NK cells and subsequently found
on different T cell subsets, especially CD8+T cells[7,8]. The
ligand for these receptors was the nonclassical class I mol-
ecule, Qa-1 in mice, and its homologue HLA-E in humans
[9-11]. By binding to different NKG2 subsets, CD94 could
regulate the cytotoxicity and survival of NK cells and
CD8+T cells upon reaction with their ligand [12-15].
Recently, a few studies reported that CD94 was associated
with the regulatory function of NK cells and CD8+T cells.
Della Chiesa and coworkers[16] found that a NK cell sub-
set expressing CD94-NKG2A in lymph nodes was capable
of killing immature DC and mature DC to prevent the
overactivation of DCs. Using DNA microarray analysis,
Keino et al[17] compared patterns of gene expression in
regulatory OT-1 CD8+T cells generated in vitro with those
from nonregulatory OT-1 CD8+T cells. They found that
CD94 mRNA was up-regulated in OT-1 CD8+Tregs, sug-
gesting that CD94 may play a role in immune regulation
by Tregs. Chattopadhyay et al[18] extended this study and
reported that mice with deficiency of CD94-NKG2A were
unable to develop ACAID, and CD8+T cells from these
mice did not transfer the local suppression of a DTH
response. Their study indicated that the CD94 molecule is
necessary for the immunosuppression mediated by
CD8+Treg in ACAID. However, the suppressive mecha-
nism and characteristics of CD8+CD94+T in ACAID
remain unclear. The present study showed that CD94 was
up-regulated on CD8+T cells from the spleens of ACAID
mice. Very few CD8+CD94+T cells express granzyme B,
perforin and Foxp3. CD8+CD94+T cells, but not
CD8+CD94-T cells from ACAID mice exhibited suppres-
sive activity in association with enhanced expression of
TGF-beta1. These results suggest that CD8+Treg in ACAID
are mainly distributed in CD94+T cell subpopulations.
Results
Upregulation of the CD94-NKG2A receptor on splenic 
CD8+T cells of ACAID mice
RT-PCR and flow cytometry were used to investigate the
expression of CD94 and NKG2A on CD8+T cells at the
mRNA and protein level during ACAID. As shown in Fig-
ure 1, mRNA of CD94 and NKG2A was detectable on
CD8+T cells in all groups, but it was significantly higher in
ACAID mice as compared to immunized mice, OVA-AC-
injected mice, PBS-AC-injected mice and naïve mice. The
expression of these two molecules in immunized mice
and OVA-AC-injected mice was also significantly higher
than that observed in PBS-AC-injected mice and naïve
mice. As shown in Figure 2, the frequencies of CD94 and
NKG2A expression on CD8+T cells from spleens were sig-
nificantly higher in ACAID mice(8.68%, 2.92%) com-
pared with immunized mice(6.0%, 2.2%), OVA-AC-
injected mice(5.84%, 2.25%), PBS-AC-injected
mice(2.65%, 1.27%) and naïve mice(2.56%, 1.21%). The
OVA-AC-injected mice and immunized mice also showed
significantly increased frequencies of splenic
CD8+CD94+T and CD8+NKG2A+T cells compared with
PBS-AC-injected mice and naive mice.
Expression of perforin, granzyme B and Foxp3 in 
CD8+CD94+T cells was minimal
To characterize CD8+CD94+T cells, we examined the
intracellular expression of granzyme B, perforin and
Foxp3. As shown in Figure 3, the expression of intracellu-
lar granzyme B, perforin and Foxp3 in fresh CD8+CD94+T
cells was minimal(~0.04%, ~0.01% and ~0.01%) in
ACAID mice, immunized mice, PBS-AC-injected mice and
naïve mice. There was no significant difference among dif-
ferent groups.
CD8+CD94+T cells from ACAID mice exhibited suppressive 
activity in vitro
Splenic CD8+CD94+T and CD8+CD94-T cells were mag-
netically sorted from ACAID mice and immunized mice
and were shown to be over 90% pure (Fig. 4A). Purified
CD8+CD94+T cells from two groups displayed hypore-
sponsiveness to stimulation with anti-CD3 mAb, whereas
CD8+CD94-T cells proliferated strongly (Fig. 4B). We next
investigated whether these two subsets had suppressive
effect on the proliferation of responder cells when
exposed to OVA and anti-CD3 mAb in vitro. As shown in
Figure 4C, CD8+CD94+T cells, but not CD8+CD94-T cells,
from ACAID mice showed a significantly suppressive
effect on the proliferation of splenic mononuclear cells
(MNC) from mice with conventional immunization in a
dose-dependent manner. However, both CD8+CD94+T
cells and CD8+CD94-T cells from immunized group did
not exhibit this suppression. Additionally, OVA-AC-
induced CD8+CD94+T cells did not influence the prolifer-
ation of splenic MNC from naive mice when exposed to
the anti-CD3 mAb stimulation (Fig. 4D).
Suppressive activity of CD8+CD94+T cells in ACAID was 
associated with TGF-beta1 production
An ELISA was used to measure IL-10 and TGF-beta1 in the
supernatants of the cultures containing APC, OVA,
CD8+CD94+T or CD8+CD94-T cells. The results showed
that both CD8+CD94+T and CD8+CD94-T cells in ACAID
mice could equally produced a large amount of IL-10,
which was significantly higher than that in mice following
conventional immunization (Fig. 5A). Interestingly,
CD8+CD94+T cells from ACAID mice secreted larger
amounts of TGF-beta1 as compared with CD8+CD94-T
cells from these mice. TGF-beta1 production from the
conventionally immunized control mice was also much
lower than that observed by CD8+CD94+T cells from
ACAID mice (Fig. 5B). A blocking experiment with anti-BMC Immunology 2008, 9:53 http://www.biomedcentral.com/1471-2172/9/53
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TGF-beta1 mAb was performed to examine its influence
on the cell proliferation. As shown in Figure 5C, neutrali-
zation of TGF-beta1 was able to decrease the
CD8+CD94+T cell suppressive activity by 27.4%. There
was still significant difference between CD8+CD94+T-
untreated group and TGF-beta1-neutralization group.
Discussion
The present study showed that expression of CD94 was
up-regulated on CD8+T cells during ACAID. CD8+CD94+T
cells were characterized by minimal expression of per-
forin, granzyme B and Foxp3. Furthermore the study
showed that the CD8+CD94+T subpopulation from
ACAID mice could significantly inhibit splenic MNC pro-
liferation in vitro and that these cells produced large
amounts of TGF-beta1. These results suggest that the
CD8+CD94+T subpopulation play a role in the immune
regulation.
Although CD94 could pair with different NKG2 mole-
cules, most CD94/NKG2 receptors on both NK and
CD8+T cells have been shown to be CD94-NKG2A het-
erodimer in mice [8,11]. We first examined the expression
of CD94 and NKG2A on splenic CD8+T cells. The results
showed that a significantly higher expression of CD94-
NKG2A heterodimer on CD8+T cells was induced follow-
ing OVA inoculation into the anterior chamber, and that
AC-injection of antigen and immunization have a syner-
gistic effect on the increase of CD8+CD94+T cells. Given
the important role of cytokines in CD94-NKG2A expres-
sion [19-23], this upregulated receptor may be due to the
promotion of certain cytokines from the splenic immu-
nomodulatory microenvironment during the induction
of ACAID. Interestingly, we also found an increased
expression of CD94-NKG2A in mice following conven-
tional immunization. This result is in agreement with the
results presented by Jabri et al[24]. They found that CD94-
Expression of CD94-NKG2A mRNA on CD8+T cells Figure 1
Expression of CD94-NKG2A mRNA on CD8+T cells. Mice underwent various treatments and were divided into naïve 
group, PBS-AC-injected group, OVA-AC-injected group, immunized group and ACAID group. A: CD8+T cells magnetically 
sorted from splenic MNC of each group were lyzed to obtain total cellular RNA using TRIzol, and RT-PCR was performed to 
analyze CD94 and NKG2A mRNA expression. B: histograms showed the mRNA expression (mean percentage ± SEM) relative 
to β-action expression (set at 100%). The results shown are representative of three independent experiments. *p < 0.05 com-
pared with naïve mice. #p < 0.05 compared with ACAID mice.BMC Immunology 2008, 9:53 http://www.biomedcentral.com/1471-2172/9/53
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NKG2A could be induced on CD8+T cells following TCR-
mediated activation in vivo.
It is well known that CTL, which are mainly found in the
CD8+T cell subpopulation, are impaired during
ACAID[25]. Analysis of the expression of perforin and
granzyme B, two important molecules for cytotoxicity, on
CD8+CD94+T only revealed a moderate expression. These
data are consistent with an earlier study we reported,
where we could not detect secretion of granzyme B by
CD8+T cells in ACAID mice, whereas production in con-
trol immunized mice was readily observed [26]. This phe-
nomenon is also confirmed by Cone et al that perforin
was not required for suppression by ACAID
CD8+Treg[27]. The very low production of granzyme B
and perforin by CD8+CD94+T cells in each group in this
study suggests that these two molecules are not involved
in the development of ACAID.
Although CD8+T cells from ACAID mice exert suppres-
sion[28,29], it is unknown that which subpopulation of
CD8+T cells exhibit suppressive activity. Chattopad-
hyay[18] et al demonstrated that DBA/2J mice, character-
ized by a deficiency in CD94/NKG2A, showed a defective
immune regulation by CD8+Treg response in vivo follow-
ing intracameral antigen inoculation. Their study sup-
ported that CD94 is necessary for the generation and
function of CD8+Treg, but no results about the suppres-
sive activity of CD8+CD94+T cells are showed. As both int-
racameral inoculation and conventional immunization
could upregulate CD94-NKG2A expression, we examined
the inhibitory effect of CD8+CD94+T cells from ACAID
Expression of CD94-NKG2A protein on CD8+T cells Figure 2
Expression of CD94-NKG2A protein on CD8+T cells. Mice underwent various treatments and were divided into naïve 
group, PBS-AC-injected group, OVA-AC-injected group, immunized group and ACAID group. A: Splenic MNC were harvested 
from each group and stained with anti-CD3, anti-CD8, anti-CD94 and anti-NKG2A mAb, then the CD3+CD8+T population 
was gated and analyzed for the expression of CD94 and NKG2A protein. B: FCM histogram showed the frequencies of 
CD8+CD94+T and CD8+NKG2A+T cells among CD8+T cells. Results represent the mean ± SEM of three separate experi-
ments. *p < 0.05 compared with naïve mice. #p < 0.05 compared with ACAID mice.BMC Immunology 2008, 9:53 http://www.biomedcentral.com/1471-2172/9/53
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mice and immunized mice on the proliferation of splenic
MNC in vitro. The results showed that only CD8+CD94+T
cells from ACAID mice profoundly inhibited the prolifer-
ation of responder cells, CD8+CD94-T cells from ACAID
mice as well as immunized mice showed no suppressive
activity. As OVA and anti-CD3 mAb was concurrently
used to stimulate MNC from the immunized mice, both
antigen-specific and non-specific suppression were meas-
ured in our system. In a pilot experiment we tried to detect
the antigen-specific suppression by using OVA alone.
However, a weak response of MNC to antigen made it dif-
ficult to compare the result between positive and suppres-
sion groups. In contrast, we found that OVA-AC-induced
CD8+CD94+T cells did not influence the proliferation of
splenic MNC from naive mice when exposed to polyclo-
nal stimulation, this result seems to suggest a property of
antigen-specific suppression of CD8+CD94+T cells in
ACAID. It is consistent with the previous observations
Expression of granzyme B, perforin and Foxp3 in CD8+CD94+T cells Figure 3
Expression of granzyme B, perforin and Foxp3 in CD8+CD94+T cells. Splenic MNC from ACAID mice, immunized 
mice, PBS-AC-injected mice and naïve mice were prepared and labeled with anti-CD3, anti-CD8, anti-CD94, anti-perforin, 
anti-granzyme B and anti-Foxp3 mAb. A: CD3+CD8+T population was gated and analyzed for the frequency of CD94+granzyme 
B+T cells. B: CD3+CD8+T population was gated and analyzed for the frequency of CD94+perforin+T cells. C: CD3+CD8+T 
population was gated and analyzed for the frequency of CD94+Foxp3+T cells. The results shown are representative of three 
independent experiments.BMC Immunology 2008, 9:53 http://www.biomedcentral.com/1471-2172/9/53
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Suppressive activity exhibited by CD8+CD94+T cells from ACAID mice in vitro Figure 4
Suppressive activity exhibited by CD8+CD94+T cells from ACAID mice in vitro. A: the purity of isolated 
CD8+CD94+T (left) and CD8+CD94-T (right) cells by magnetic affinity cell sorting; B: the response of CD8+CD94+T and 
CD8+CD94-T cells to anti-CD3 mAb stimulation (stim). *p < 0.05 compared with unstimulated group. C: suppressive effect of 
CD8+CD94+T and CD8+CD94-T cells on the proliferation of splenic MNC. Splenic MNC (5 × 104 cells/well, as responder 
cells) from immunized mice were cocultured with purified CD8+CD94+T or CD8+CD94-T cells (as regulatory cells) from 
ACAID mice and immunized mice at different responder/suppressor ratios (1:0, 1:0.25, 1:0.5 and 1:1) in the presence of 
OVA(100 μg/ml) and anti-CD3 mAb(1 μg/ml) for 72 hours and pulsed with [3H]thymidine for the last 16 hours of culture. 
Data are represented as mean ± SEM of triplicate samples. *p < 0.05 compared with stimulated MNC group. D: suppressive 
effect of CD8+CD94+T and CD8+CD94-T cells from ACAID mice on the proliferation of splenic MNC from naive mice (at 1:1 
ratio) upon anti-CD3 mAb(1 μg/ml) stimulation.BMC Immunology 2008, 9:53 http://www.biomedcentral.com/1471-2172/9/53
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IL-10 and TGF-beta1 production and the role of TGF-beta1 in immunosuppression Figure 5
IL-10 and TGF-beta1 production and the role of TGF-beta1 in immunosuppression. CD8+CD94+T or CD8+CD94-
T cells(5 × 104) from ACAID mice and immunized mice were cocultured with PEC(1 × 105) and OVA (100 μg/ml) for 72 
hours. ELISA was used to detect the concentration of IL-10 (A) and TGF-beta1 (B) in the supernatants of the cultures. *p < 
0.05 compared with immunized mice. For blocking experiments (C), anti-TGF-beta1 mAb(50 μg/ml) or matched isotype was 
added to the culture at the initiation of the cell proliferation assay, then [3H]thymidine incorporation was measured to value 
the suppressive activity of CD8+CD94+T cells from ACAID mice. Data are represented as mean ± SEM of triplicate samples. 
*p < 0.05 compared with stimulated MNC+CD8+CD94+T cell group (the second bar). #p < 0.05 compared with stimulated 
MNC group (the first bar).BMC Immunology 2008, 9:53 http://www.biomedcentral.com/1471-2172/9/53
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that CD8+T cells in ACAID are efferent antigen-specific
Tregs. Another property of CD8+CD94+T cells was hypo-
proliferation when stimulated with polyclonal stimula-
tion, this anergic state of CD8+CD94+T cells was similar to
other Tregs such as CD4+CD25+Treg[30,31]. However,
CD8+CD94-T cells did not show any suppressive activity
and anergy, suggesting the non-Treg's property of these
cells. These data suggest that the induced expression of
CD94 molecule is associated with the inhibitory effect of
CD8+T cells following OVA inoculation into the anterior
chamber.
It is interesting that CD8+CD94+T cells from ACAID mice,
but not from immunized mice exert suppression in vitro.
What results in the different suppressive activity of
CD8+CD94+T cells between tolerant mice and immunized
mice? As cells exert their function mainly through releas-
ing cytokines or contacting the target cells, it is possible
that different cytokine secretion may cause different func-
tional effects. IL-10 and TGF-beta have been shown to be
the suppressive cytokines of CD8+Treg in some models
[32-39]. Wang and collaborators found that an increased
IL-10 and TGF-beta2 were observed in the cultures con-
taining AC-splenic T cells, lymph node cells and anti-
gen[28]. Kezuka et al[40] demonstrated that TGF-beta2 is
not required for the suppression mediated by in vitro-acti-
vated OT-1 Treg, similar to ACAID CD8+Treg. We subse-
quently analyzed the production of TGF-beta1 and IL-10
to evaluate the association of these inhibitory cytokines
with suppressive property of CD8+CD94+T cells. Our
result showed that CD8+CD94+T cells from ACAID mice
produced larger amounts of TGF-beta1 and IL-10 than
those from conventionally immunized mice, suggesting
that different cytokine secretion is associated with differ-
ent inhibitory property. It is interesting to note that there
was no difference between CD8+CD94+T cells and
CD8+CD94-T cells concerning IL-10 production. The
unique increased TGF-beta1 production by the
CD8+CD94+T cells with suppressive activity in ACAID
mice raises a question as to whether these cells exert their
role via TGF-beta1. Our further experiment using anti-
TGF-beta1 antibody tested this possibility and found that
it could partially block the inhibitory activity of
CD8+CD94+T cells. The anti-TGF-beta1 antibody has been
titrated to test whether it could completely neutralize its
inhibition. Even higher concentrations still showed a par-
tial inhibition (data not shown). It has been demon-
strated that different subpopulations of CD8+Treg exert
their immunosuppression possibly by different mecha-
nisms. There may be other factors involved in this inhibi-
tion, for instance cell-cell contact, other isoforms of TGF-
beta or other cytokines. More studies are needed to clarify
these issues.
Given the different suppressive activity between
CD8+CD94+T and CD8+CD94-T cells in ACAID mice, we
thinks that CD8+Treg are mainly distributed in CD94+T
subpopulation in ACAID. However, it appears that CD94
is not a specific marker for CD8+Treg, as this molecule can
be upregulated following T cell activation and
CD8+CD94+T cells from immunized mice did not show
suppression. This phenomenon resembles the role of
CD25, CTLA-4 and GITR in identifying CD4+Treg. What is
the specific marker for CD8+Treg? Recent studies reported
that one population of CD8+Tregs was associated with
Foxp3 expression [41-43], we further examined the
expression of Foxp3 by CD8+CD94+T cells. Our data
showed that very few CD8+CD94+T cells expressed Foxp3
and there was no significant difference among different
experimental groups. Earlier studies from our group also
showed a very low expression of Foxp3 by CD8+T cells,
but the frequency of CD8+Foxp3+ cells in splenocytes of
ACAID mice was upregulated following polyclonal or spe-
cific antigen stimulation in vitro[29]. In the present study,
splenocytes were not treated with any stimulation, which
may explain why we did not detect any significant differ-
ence in Foxp3 expression among the different groups. Our
results support the opinion provided by Ahmadzadeh et
al[44] that Foxp3 can not be simply interpreted as an indi-
cator of Treg activity. Our study also suggests that
CD8+CD94+ T cells may be only one population of CD8+
Treg.
Conclusion
The data presented in this paper showed that
CD8+CD94+T cells from ACAID mice exhibited suppres-
sive activity in association with enhanced expression of
TGF-beta1, suggesting CD8+Treg may be mainly distrib-
uted in CD94+T subpopulation in ACAID. However, it
appears that CD94 is not a specific marker for CD8+Treg,
because this molecule is associated with CD8+T cell acti-
vation and no suppression was observed by CD8+CD94+T
cells from immunized mice. There are also some limita-
tions in our study. The profile of cytokines by
CD8+CD94+T remains unclear. Due to the low number of
CD8+CD94+T cells from ACAID mice, we were not able to
perform adoptive transfer experiments. More studies
using more sensitive techniques and more experiments
are needed to clarify the role of CD8+CD94+ T cells in the
development of ACAID. As NKT cells may be positive for
both CD8 and CD94 molecules [45-47], the isolated
CD8+CD94+ T cells in this study may contain NKT cells.
Methods
Mice
Female C57BL/6 (B6; H-2b) mice, 6 to 8 weeks of age,
were purchased from the animal facility at the Sun Yat-Sen
University, P.R. China. All mice were treated according toBMC Immunology 2008, 9:53 http://www.biomedcentral.com/1471-2172/9/53
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the ARVO Statement for the Use of Animals in Ophthal-
mic and Vision Research.
Induction of ACAID
ACAID was induced as described previously using micro-
injection of antigen into the AC of the eye[48]. Briefly,
mice were anesthetized with inhalation anesthesia con-
sisting of oxygen and 1.7% isoflurane followed by injec-
tion of 5 μl ovalbumin at 20 mg/ml (OVA, Sigma, St.
Louis, MO) into the AC by a glass micropipette with a ster-
ile infant feeding tube mounted onto a 0.1 ml Hamilton
(Hamilton, Reno, NV) syringe. Seven days later, mice
received a subcutaneous (s.c.) immunization with 250 μg
OVA dissolved in PBS and emulsified in complete Fre-
und's adjuvant (Life Technologies, Grand Island, NY).
Mice only receiving subcutaneous injections of OVA in
CFA were used as immunized controls (OVA s.c.). Mice
receiving an AC-injection of 5 μl sterile PBS alone served
as PBS-AC-injected controls (PBS a.c.). Mice receiving an
AC-injection of 5 μl OVA without subsequent immuniza-
tion served as OVA-AC-injected controls (OVA a.c.).
Preparation of peritoneal exudate cells
Peritoneal exudate cells (PECs) were obtained from nor-
mal C57BL/6 mice that received 2 ml of thioglycolate
(Sigma Chemical Co.) intraperitoneally three days earlier.
Briefly, the recovered cells were washed and resuspended,
placed in a 24-well culture plate (1 × 106/well), and incu-
bated in complete RPMI 1640 medium at 37°C in an
atmosphere of 5% CO2. After overnight culture, plates
were washed three times with culture medium to remove
nonadherent cells. Adherent cells were retained in the
wells and used as antigen-presenting cells (APC). More
than 90% of these adherent cells were F4/80+ as identified
by subsequent FCM analysis.
Reverse transcription-PCR
Total cellular RNA was isolated from 5 × 106 freshly puri-
fied splenic CD8+T cells of the experimental and control
mice using Trizol (Invitrogen, San Diego, CA). Single-
strand cDNA was synthesized with an RT-PCR kit (Qia-
gen, Hilden, Germany) according to the manufacturer's
instructions. The following primers were used: CD94-FW,
5'-TTTCTTGATGGTTACTTTGGGAGTT-3'; CD94-RV, 5'-
AAACGCTTTTGCTTGGACTGTA-3'; NKG2A-FW, 5'-
CAGTCATCGAGCAGGAAATC-3'; NKG2A-RV, 5'-GCT-
GACCTCTGCCCTTCCGA-3';  β-actin-FW, 5'-GTCCCT-
CACCCTCCCAAAAG-3';  β-actin-RV, 5'-
GCTGCCTCAACACCTCAACCC-3'. PCR was performed
with a initially heating to 94°C for 5 min followed by 30
cycles at 94°C for 30 s, 60°C for 30 s, and 72°C for 60 s.
Splenocytes from four mice were used in each group in
one experiment. The experiment was repeated three times.
Flow cytometry
For cell surface staining, splenocytes(1 × 106) were stained
with FITC or PE-Cy7-anti-CD3 mAb, APC or FITC anti-
CD8 mAb, PE anti-CD94 mAb, PE-anti-NKG2A mAb for
30 minutes at 4°C in the dark. For intracellular cytokine
staining, cells were first stained for surface markers fol-
lowed by fixation and permeabilization, and were then
stained with APC-anti-perforin mAb, FITC-anti-granzyme
B mAb, APC-anti-Foxp3 mAb or matched isotypes accord-
ing to the manufacturer's instructions. Phenotypic analy-
sis was performed on a BD FACSAria(BD Biosciences, San
Jose, CA) using the BD FACSDiVa software (BD Bio-
sciences). All conjugated antibodies were purchased from
eBioscience(San Diego, CA). Four mice were used for each
group in one experiment. These experiments were
repeated three times.
Magnetic affinity cell sorting
Splenic mononuclear cells (MNC) were prepared by den-
sity gradient centrifugation. CD8+T cells were purified
from splenic MNC of C57BL/6 mice by negative selection
using a CD8+T-cell isolation kit (Miltenyi Biotec, Auburn,
CA) according to the manufacture's instructions. Enriched
CD8+T cells were stained with PE-conjugated anti-mouse
CD94 mAb (eBioscience, San Diego, CA) for 30 minutes
at 4°C in the dark followed by anti-PE microbeads
(Miltenyi Biotec) for 15 minutes at 4°C. A positive selec-
tion was performed and both CD8+CD94+T and
CD8+CD94-T cells were isolated as described by the man-
ufacturer. The purity of CD8+CD94+T and CD8+CD94-T
cells was > 90% as determined by subsequent FCM analy-
sis.
Proliferation and cytokine assays
Splenic MNC (5 × 104 cells/well, as responder cells) from
immunized mice were cocultured with purified
CD8+CD94+T or CD8+CD94-T cells (as regulatory cells)
from ACAID mice and immunized mice at different
responder/suppressor ratios (1:0, 1:0.25, 1:0.5, 1:1) in the
presence or absence of OVA(100 μg/ml) and anti-CD3
mAb(1 μg/ml) (eBioscience, San Diego, CA) for 72 hours
and pulsed with [3H]thymidine (Shanghai Institute of
Applied Physics, Chinese Academy of Sciences, China) for
the last 16 hours of culture. [3H]thymidine incorporation
was determined by scintillation spectrometry. The sup-
pressive effect of CD8+CD94+T and CD8+CD94-T cells
from ACAID mice on the proliferation of splenic MNC
from naive mice (at 1:1 ratio) upon anti-CD3 mAb(1 μg/
ml) stimulation was examined. In addition, the prolifera-
tion of CD8+CD94+T and CD8+CD94-T cells (5 × 104
cells/well) from ACAID mice and immunized mice to the
polyclonal stimulation was also examined. In order to
clarify whether TGF-beta1 has an effect on suppression
mediated by CD8+CD94+T cells from ACAID mice, addi-
tional proliferation assays were performed after blockingBMC Immunology 2008, 9:53 http://www.biomedcentral.com/1471-2172/9/53
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with anti-TGF beta1 mAb or matched isotype(R&D Sys-
tems, Inc, USA). Proliferation data were expressed as
mean cpm ± SEM of triplicate reactions. To detect IL-10
and TGF-beta1 production, freshly isolated splenic
CD8+CD94+T or CD8+CD94-T cells from various groups
of mice were cultured in the 96-well plates containing
PECs(1 × 105/well) and OVA(100 μg/ml) for 72 hours.
Supernatants were collected and assayed by ELISA (R&D
system, Minneapolis, MN, USA) according to the manu-
facturer's instructions. Four mice were used for each group
in one experiment. The experiment was repeated three
times.
Statistical analyses
All statistical analyses were performed by ANOVA using
SPSS 11.0. A value of p < 0.05 was considered significantly
different.
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